This year’s Nordic Life Science Days took place in Copenhagen on 29-30 November.
Since 2015, Oslo Cancer Cluster has coordinated the joint booth Norway for Life Science, promoting the Norwegian healthcare and life science industry. This year together with Norway Health Tech, The Life Science Cluster, Norwegian Smart Care Cluster, Centre for Digital Life Norway, NorTrials, Aleap, Legemiddelindustrien (LMI), Inven2, Innovation Norway, the Royal Norwegian Embassy in Copenhagen and Curida.
Our members on stage
Anette Weyergang, CEO at RAB Diagniostics, a new company that works towards making cancer treatment more effective and match the right patient with the right drug. RAB Diagniostics is a part of Oslo Cancer Clusters Incubator accelerator program which provide the project with business development.
Weyergang is a pharmacist by education and has spent her career since 2004 in Professor Kristian Berg’s research group at the Institute for Cancer Research.
It was great fun pitching RAB Diagniostics in this environment at NLS days, I wish I had more than 4 minutes on stage to talk about our ongoing mission, which is to help finding the right patients so that we can spare those who are less likely to respond to unnecessary treatments.
Find more information about RAB Diagnostics here
Adam Robertson, Chief Scientific Officer at Hemispherian, was thrilled to present at Nordic Life Science days. Hemispherian is an innovative preclinical pharmaceutical company focused on developing a novel class of small molecule drugs.
Presenting at NLS Days was an exciting experience. I am glad that so many participants were able to attend. Being a part of such high calibre pitches is hugely motivating.
Hemispherian is at the forefront of revolutionizing cancer treatment, offering hope and potential solutions for patients facing hard-to-treat cancers, especially glioblastoma. The company will enter clinical development in 2024. Robertson shares that Hemispherian’s drug candidates have shown excellent efficacy including in orthotopic glioblastoma xenograft models, as well as excellent tolerability in several animal models.
Find more information about Hemispherian here
Torbjørn Furuseth, CEO and co-founder of DoMore! Diagnostics, presented the latest development and new results from tthis years research and projects.
Find more information about DoMore! Diagnostics here
Hanne Lund, Business Development Director at Curida, talked about the newest updates from the company in 2023.
Find more information about Curida here